Management Team & Board of Directors

About Us

MIMEDX has built a management team of highly experienced executives with track records of leading large healthcare organizations in generating growth, producing profitability, and increasing shareholder value. Our management team draws on guidance from an insightful board of directors and scientific advisory board. Collectively, they are committed to driving performance, accomplishing our corporate goals, and growing the company.

Management Team

Joseph H. Capper
Chief Executive Officer

Doug Rice
Chief Financial Officer

John Harper, Ph.D.
Chief Scientific Officer and SVP, Research and Product Development

William F. “Butch” Hulse
General Counsel and Chief Administrative and Compliance Officer

Kim Moller
SVP, Sales

Eric Smith
SVP, Marketing & International

Kate Surdez
Chief Human Resources Officer

Ricci Whitlow
Chief Operating Officer

Board of Directors

M. Kathleen Behrens, Ph.D.
Chair of the Board

Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009 (Chairwoman of the Board since April 2015) and IGM Biosciences, Inc., a privately held biotechnology company, since January 2019.

Joseph H. Capper
Chief Executive Officer

Mr. Capper joined MIMEDX in January 2023 to lead the Company as Chief Executive Officer and Director. A highly experienced and accomplished healthcare executive, he brings nearly 30 years of experience in MedTech and Life Sciences leadership roles along with a track record of substantial value creation.

James L. Bierman

Mr. Bierman served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015.

Phyllis I. Gardner, M.D.

Dr. Gardner has spent more than 35 years in academia, medicine and industry. She has served on the board of directors of several public and private companies, including Revance Therapeutics, Inc. since 2006, Corium International, Inc. from November 2007 to December 2018, and CohBar, Inc. from February 2019 to present.

Michael J. Giuliani, M.D.

Since July 2016, Dr. Giuliani has been a consultant for several small pharmaceutical companies and has provided expert testimony for Mallinckrodt Pharmaceuticals.

William A. Hawkins III

Mr. Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology.

Cato T. Laurencin, M.D., Ph.D., NACD.DC

Dr. Laurencin currently serves the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated University Professors at the school.

K. Todd Newton

Mr. Newton joined MIMEDX’s Board in 2019, and has since served as Chair of the Audit Committee and as a member of the Ethics and Compliance Committee.

Martin P. Sutter

Since 1985, Mr. Sutter has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm.